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Abstract  
 
Objectives   
To examine the long-term risk of thromboembolism and bleeding in patients with atrial 
fibrillation comparing patients with and without recent breast cancer in subgroups with 
or without anticoagulation therapy, respectively. 
Design 
Using nationwide registries, patients with breast cancer from 1998-2015 and subsequent 
atrial fibrillation within 3 years were stratified on anticoagulation and matched 1:3 on 
age, sex and comorbidities with atrial fibrillation patients without breast cancer. Risks 
of thromboembolism and bleeding were estimated by Aalen-Johansen and multivariable 
cox regression models. 
Results 
Atrial fibrillation patients with and without anticoagulation were matched, respectively 
(201 and 525 with breast cancer matched with 603 and 1,575 without breast cancer). In 
patients with CHA2DS2-VASc-score >1 and anticoagulation the three years risks of 
thromboembolism were 4.2% (95% confidence interval (CI) 1.1-7.3) and 3.2 % (CI 1.5-
4.9) in patients with and without breast cancer. The risks of bleeding were 5.3% (CI 
1.7-8.9) and 5.1% (CI 3.0-7.1), respectively. Breast cancer was associated with a similar 
risk of thromboembolism in patients with and without anticoagulation, respectively 
(Hazard ratio (HR) 1.10, CI 0.63-1.92 and HR 1.11, CI 0.82-1.50) and a similar risk of 
bleeding in patients with and without anticoagulation, respectively (HR 1.01, CI 0.56-
1.84 and HR 0.85, CI 0.57-1.27) compared with the matched controls. 
Conclusions  
Breast cancer was not associated with altered risk of thromboembolism or bleeding in 
patients with atrial fibrillation irrespective of treatment with anticoagulation. Our 
analyses suggest that atrial fibrillation diagnosed in patients with breast cancer should 
be considered as primary atrial fibrillation. 
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Breast cancer (BC) is the most common cancer among women worldwide, but it is not the 
leading cause of cancer related death.[1] The good prognosis is probably due to the effective 
diagnostics and treatments used, and today most patients with BC will become long term 
survivors.[2] However, survivorship may be hampered by side effects, cardiovascular side 
effects in particular.[3–5] Patients with BC may have greater risk of developing atrial 
fibrillation (AF) than the background population.[6] [7]Additionally, the risks of 
thromboembolism and bleeding associated with AF in patients with recent BC are unknown. 
Information on risk of thromboembolism in patients with BC is scarce, and both increased[8], 
similar[9–13], and decreased risks[14] have been reported in studies comparing patients with 
BC with the background population with no information of presence of AF. A single study 
has found similar risks of thromboembolism and bleeding associated with anticoagulation in 
patients with AF and prior BC.[13] Furthermore, the current anticoagulation guidelines 
provides no recommendations regarding these patients.[15,16] In order to address this 
knowledge gap[17,18], we examined the long-term risks of thromboembolism and bleeding in 
AF patients with BC compared with AF patients without BC in analyses stratified on 
anticoagulation.  
 
Materials and methods 
Nationwide databases 
The Danish health care system is tax financed and accessible to all citizens without charge. 
All Danish citizens have a unique permanent identification number that is registered every 
time the citizen uses a healthcare service. This system enables linkage of information from 











databases. The Danish Civil Registration System holds information on identification number 
and date of birth.[19] The Danish Register of Causes of Death has information on vital status 
and date and cause of death.[20] The Danish National Patient Registry holds information on 
admissions, discharges and outpatient contacts from Danish hospitals since 1978 including 
international classification of diseases (ICD-10) codes.[21] Definitions based on ICD-10 
codes from the Danish National Patient Register have an overall high validity, e.g. stroke 
(I60-64) has a high positive predictive value of 97%.[21,22]  Finally, the Danish National 
Prescription Registry holds all prescriptions dispensed from Danish pharmacies complete with 
data on expedition date, drug type, dose, quantity and anatomical therapeutic chemical (ATC) 
classification code.[23]   
Study population 
All female patients diagnosed with BC from 1st of January 2000 to 31st of November 2015 
were identified and included after a quarantine period of 30 days. The quarantine period 
ensured that BC and AF were not diagnosed during the same hospitalization, and that BC 
preceded AF in the individuals of the study population. Patients who developed incident AF 
within 3 years after this date were included in the study, and the index date was 14 days after 
the discharge date following hospitalization for AF. AF was defined as being discharged after 
hospitalization with AF as the primary diagnosis (ICD-10 code I-48 AF or atrial flutter). The 
definition has been shown to have a positive predictive value of 93% and a 6% proportion of 
patients with atrial flutter.  Exclusion criteria were age < 18 or > 100 years at index, AF prior 
to BC, anticoagulation or antiarrhythmic therapy within 6 months preceding AF 
hospitalization, prior valvular heart disease, missing data or emigration before the index date. 
The patients were grouped according to anticoagulation at baseline. Receiving anticoagulation 











days following hospitalization for AF. Later prescription fillings were not assessed. The 
patients were then followed for 3 years and observed for the outcomes thromboembolism and 
bleeding and the competing risk of death. Censoring was performed at the end of follow up 
(maximum 3 years) or if a patient emigrated during the study period.   
Outcomes, comorbidities and pharmacotherapy 
We analyzed the two primary outcomes thromboembolism and bleeding in separate analyses 
with all cause death as the secondary outcome. In all analyses a primary event censored any 
secondary events. The outcomes thromboembolism and bleeding were based on ICD-10 
discharge diagnoses after hospitalization and death causes. Admissions with 
thromboembolism and bleeding, respectively, as the primary diagnosis were defined as 
events. Additionally, death caused by stroke was defined as an event.  
Baseline comorbidities were defined as registration with discharge diagnoses or outpatient 
contacts within 5 years preceding index date as listed in Table 1. Baseline treatment with a 
specific drug was defined as redeemed prescriptions during the 6 months preceding inclusion 
to the study. The definitions based on ICD-10 codes and ATC codes are described in 
Supplementary Table A.1.  
Statistical methods 
The study population was stratified according to anticoagulation at baseline yielding two 
subpopulations; a subpopulation with and a subpopulation without anticoagulation. Risk-set 
matching using the R package ‘heaven’ was used to match women with BC and incident AF 
1:3 with women with incident AF without BC on the match criteria age, diabetes mellitus, 
hypertension, heart failure, stroke, and history of thrombosis in the two subpopulations, 











matching criteria and subsequently consecutively selected unique controls without outcomes 
prior to the study start of the cases they were matched to. Incidence rates per 100 person years 
were estimated. The Aalen-Johansen non-parametric method was used for generating 
cumulative incidence estimates and curves with competing risk of death. Cox proportional 
hazards regression models were applied to analyze the associations between BC and 
thromboembolism and bleeding, respectively. The models used to analyze the associations in 
the subpopulation with anticoagulation were adjusted for chronic kidney disease and the 
models used to analyze the associations in the subpopulation without anticoagulation were 
additionally adjusted for chronic liver disease. All models were stratified according to the 
matching and tested for proportional hazards of the covariates.  As a sensitivity analysis we 
conducted the same cox models additionally adjusted for statins and aspirin therapy. The 
Mann-Whitney test was used to test for differences in the time interval from BC to AF 
diagnosis between patients with and without anticoagulation. Statistical significance was 
defined as two-sided p-value <0.05. Parameter estimates were reported with 95% confidence 
intervals (CI), means with standard deviations, and medians with interquartile range (IQR). 
Statistical analyses were performed using SAS Software version 9.4 (SAS Institute Inc.) and 
R: A language and environment for statistical computing.[25]  
 
Results  
A total of 726 patients with BC developed AF within 3 years after discharge. Among patients 
with BC and AF 201 were treated with anticoagulation; 136 (67.6%) with vitamin K 
antagonists, 59 (29.4%) with non-vitamin K oral anticoagulation (NOAC) and 8 (4%) with 
heparins. Among the controls with AF without BC 603 were treated with anticoagulation; 312 











The median time interval from BC to AF diagnoses was 1.52 years (IQR 0.73-2.32) for 
patients with anticoagulation and 1.36 years (IQR 0.57-2.19) for patients without 
anticoagulation. We found no difference in time intervals comparing AF patients with and 
without BC (Mann-Whitney test, p=0.1). In the subpopulation with anticoagulation 201 AF 
patients with BC matched with 603 AF patients without BC, while in the subpopulation 
without anticoagulation 525 AF patients with BC matched with 1,575 AF patients without 
BC. The inclusion is depicted in Figure 1 and baseline characteristics are described in Table 
1.  
Cumulative incidence of thromboembolism, bleeding and mortality 
The three year cumulative incidence analyses were stratified according to CHA2DS2VASc 
score >1 or =0. In AF patients with CHA2DS2VASc scores >1 and anticoagulation the three 
year risk of thromboembolism was 4.2% (95% CI 1.1-7.3) in patients with BC and 3.2% 
(95% CI 1.5-4.9) in patients without BC. The risks of bleeding were 5.3% (95% CI 1.7-8.9) 
and 5.1% (95% CI 3.0-7.1), and the mortality risks were 21.9% (95% CI 15.3-28.4) and 
17.6% (95% CI 13.9-21.3) in patients with and without BC, respectively. We found no 
differences in the three year risks comparing patients with and without BC (Fine-Gray’s test, 
p=0.5 for thromboembolism, p=0.9 for bleeding and p=0.2 for mortality). In AF patients with 
CHA2DS2VASc scores >1 without anticoagulation the three year risk of thromboembolism 
was 4.3% (95% CI 2.4-6.3) in patients with BC and 5.2% (95% CI 3.9-6.4) in patients without 
BC. The risks of bleeding were 3.5% (95% CI 1.7-5.2) and 5.8 (95% CI 4.5-7.1) and the 
mortality risks were 47.1% (95% CI 42.4-51.8) and 28.3% (95% CI 25.8-30.9) in patients 
with and without BC, respectively. We found an increased mortality risk (Fine-Gray’s test, 
p<0.0001) and a similar risk of thromboembolism and bleeding (Fine-Gray’s test, p=0.7and 
p=0.06) comparing patients with and without BC. The curves on 3 year cumulative incidences 











Multivariable cox regression analyses 
In multivariable cox regression models stratified according to the matching and adjusted for 
relevant baseline comorbidities, we found that BC was associated with a similar risk of 
thromboembolism and bleeding in patients treated with anticoagulation (thromboembolism: 
Hazard ratio (HR) 1.10, 95% CI 0.63-1.92, p=0.73 and bleeding: HR 1.01, 95% CI 0.56-1.84, 
p=0.97) and in patients not treated with anticoagulation (thromboembolism: HR 1.11, 95% CI 
0.82-1.50, p=0.49 and bleeding: HR 0.85, 95% CI 0.57-1.27, p=0.43). The HRs and incidence 
rates are displayed in Figure 3. Additional adjustment for statins and aspirin use at baseline 
yielded results similar to the main analyses.  
 
Discussion 
In the current study we investigated the long term risks of thromboembolism and bleeding in 
a contemporary nationwide cohort of patients with AF and recent BC. The study had two 
major findings; 1) the three year risks of thromboembolism were similar, and 2) the three 
years risks of bleeding were similar in patients with AF comparing patients with and without 
recent BC. The findings were consistent in both patients with and without anticoagulation 
therapy.   
The risks of thromboembolism 
The similar risks of thromboembolism in patients with AF with and without recent BC who 
were not treated with anticoagulation, is a novel finding. The current study adds important 
knowledge to the field, as most previous research has investigated the risk of stroke in BC 
patients regardless of AF[9–11] or has focused on the in-hospital risk of cerebrovascular 
outcomes.[14] A study of 10 year survivors of BC from 1970-1986[9] and cohort studies on 











in patients with BC compared with the female background population. Conversely, a 
Scandinavian cohort study found a higher risk of stroke in BC patients diagnosed from 1970-
2000 compared with the background population (relative risk 1.12 (95% CI 1.07–1.17)).[8] 
Regarding patients treated with anticoagulation a recent study supports the finding, that 
thromboembolic and bleeding risks were similar in patients with AF with and without recent 
cancer, including BC.[13] 
The risks of bleeding 
Another main finding of this study was the similar risks of bleeding in patients with AF 
comparing patients with and without BC in the subpopulations with and without 
anticoagulation, respectively. A recent study has reported an increased risk of bleeding in AF 
patients with a history of unspecified cancer.[12] However, the body of previous research has 
focused on associations between active cancer (different cancer types) and the related 
treatments and increased risk of bleeding.[26,27] These studies examined cancer patients in 
general, not patients with BC separately, and did not control for presence of AF, 
anticoagulation therapy or CHA2DS2-VASc score. Our results suggest that AF patients with 
recent BC suffer from bleeding complications to the same extent as regular AF patients, as it 
has been shown for unspecified cancer patients[28] and for patients with AF and BC who 
were treated with anticoagulation.[13] 
Atrial fibrillation in patients with recent breast cancer 
The findings from this study indicate that AF in patients with recent BC may be considered as 
primary AF. Our results underline that patients with BC should be included in future 
randomized controlled trials on thrombo-prophylaxis in AF patients to assess the cost/benefit 
balance.[17,18] Notably, the current guidelines have no recommendations for anticoagulation 











in the field.  In this study the frequencies of patients treated with vitamin K antagonists, 
NOACs and heparins, respectively, were different comparing patients with AF with and 
without recent BC. Future studies investigating different anticoagulation strategies and 
outcomes in patients with recent breast cancer would be highly relevant.  
Mortality risks 
The 3 year mortality risks in this study were higher than estimates from the major randomized 
controlled trials on anticoagulation in AF patients.[29–33] However, this was expected, as our 
study comprised real world patients who were older and had more comorbidities than the 
study populations from the mentioned randomized trials. A Scandinavian cohort study of 
patients with AF with and without warfarin found 3 year mortality estimates similar to the 
risks in this study.[34] In line with existing knowledge we found increased mortality risk in 
AF patients without anticoagulation comparing patients with and without BC.[35] However, 
in patients with AF and anticoagulation the three year mortality risk was similar comparing 
patients with and without BC. The latter finding was potentially explained by confounding by 
indication. Confounding by indication could occur, if patients with BC and a good or 
moderate prognosis were treated with anticoagulation more often than patients with a poor 
prognosis.  
Strengths and limitations  
The study was a nationwide real life cohort study including all patients with BC and 
subsequent AF in a 15 year inclusion period. We aimed to investigate whether AF in 
conjunction with breast cancer was associated with increased risks of thromboembolism and 
bleeding. For this reason the inclusion criterion of development of AF within the first 3 years 
after breast cancer diagnosis was chosen. Additionally, we chose to conduct a strict exclusion 











were truly patients with incident AF. However, the numbers of patients and events were 
relatively small, influencing the power of the statistical analyses, but at the same time 
reflecting real life conditions. The results provide unique estimates for patients with recent 
BC developing AF, which we hope will be of use to the clinicians treating this patient group. 
The study population was comprised of unselected patients grouped by anticoagulation and 
matched on age, sex and CHA2DS2-VASc score components to raise more comparable 
groups. Furthermore, all patients had a full follow up with valid information on endpoints. 
The outcomes thromboembolism and bleeding, respectively, included only patients admitted 
with the diagnosis as their primary diagnosis. This definition was chosen to ensure that the 
diagnoses were of clinical importance. Alternatively, if outpatient contacts with 
thromboembolism and bleeding had been included the events would have been more 
heterogenic and the analyses would have been based on complications that would probably 
not restrain OAC in the clinic. 
A number of clinical conditions and baseline characteristics could be suspected of 
confounding the analyses. To control for the known and registered confounders such as age, 
sex, baseline comorbidity and CHA2DS2-VASc score, we used conventional methods. We 
matched on age and CHA2DS2-VASc score components and adjusted for baseline 
comorbidities in the regression analyses. We did not have information on stage of BC or 
related adjuvant treatment, what may have caused residual confounding to some extent. 
Especially tamoxifen and aromatase inhibitors, used in adjuvant treatment of estrogen 
sensitive BC, have been suspected of increasing the risk of cardiovascular disease.[36]  
The study was designed as an intention to treat analysis. We defined anticoagulation treatment 
as having a prescription for anticoagulation filled within the first 14 days of discharge after 











treatment, future studies of the exposure duration of anticoagulation and associated risks of 
thromboembolism and bleeding are of interest.  
In this study we focused on the risk of thromboembolism developed in patients with both 
recent BC and subsequent AF. We did not investigate the risk of other stroke etiologies in 
patient with recent BC, but the issue constitutes a relevant future research question, as this 
risk may be increased.  
As this study was an observational cohort study and not a randomized controlled trial, 
we cannot make inferences on causality or effect of anticoagulation treatment, but merely 
refer the observed associations.  
 
Conclusion  
In conclusion the three year risks of thromboembolism and bleeding were similar in patients 
with AF and recent BC compared with patients with AF without BC among both patients with 
and without anticoagulation treatment. Our results suggest that AF in conjunction with BC 
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Figure 1: Study population. AF: atrial fibrillation. CPR: Central person registration number.  
Figure 2: Three years cumulative incidence of outcomes in patients with CHA2DS2-
VASc score >1 stratified on baseline anticoagulation treatment. Figure 2A: 
Thromboembolism and bleeding. Figure 2B: Mortality. Patients with atrial fibrillation and 
recent breast cancer are compared with patients with atrial fibrillation without breast cancer. 
AC: anticoagulation. AF: atrial fibrillation. BC: breast cancer. 
Figure 3: Number of events, incidence rates pr.100 person years and hazard ratios from 
multivariable cox regression models. Patients with atrial fibrillation and recent breast cancer 
are compared with patients with atrial fibrillation without breast cancer. AF: atrial fibrillation. 













Table 1: Baseline characteristics in patients with atrial fibrillation (AF) according to 
treatment with anticoagulation and history of breast cancer (BC).  
 Anticoagulation   No Anticoagulation   
 






Age, median [IQR] 76 [69, 82] 76 [69, 82] 1.000 77 [66, 85] 77 [66, 85] 1.000 
Medical history 
      
Hypertension, n (%) 405 (67.2) 135 (67.2) 1.000 819 (52.0) 273 (52.0) 1.000 
Heart failure, n (%) 108 (17.9) 36 (17.9) 1.000 201 (12.8) 67 (12.8) 1.000 
Diabetes mellitus, n (%) 54 (9.0) 18 (9.0) 1.000 93 (5.9) 31 (5.9) 1.000 
Stroke, n (%)  66 (10.9) 22 (10.9) 1.000 81 (5.1) 27 (5.1) 1.000 
Vascular disease, n (%) 117 (19.4) 39 (19.4) 1.000 237 (15.0) 79 (15.0) 1.000 
Ischemic heart disease, n (%) 102 (16.9) 35 (17.4) 0.957 209 (13.3) 72 (13.7) 0.853 
Thyroid disease, n (%) 85 (14.1) 24 (11.9) 0.513 185 (11.7) 57 (10.9) 0.636 
Chronic kidney disease, n (%) 12 (2.0) 4 (2.0) 1.000 65 (4.1) 19 (3.6) 0.700 
Peripheral arterial disease, n (%) 22 (3.6) 5 (2.5) 0.572 42 (2.7) 12 (2.3) 0.750 
Chronic obstructive pulmonary disease, n (%) 70 (11.6) 35 (17.4) 0.046 218 (13.8) 60 (11.4) 0.181 
Chronic liver disease, n (%) <3 <3 1.000 27 (1.7) 11 (2.1) 0.705 
Diagnoses related to increased alcohol assumption, n (%) 5 (0.8) <3 1.000 31 (2.0) 9 (1.7) 0.854 
CHA2DS2-VASc score >1, n (%) 579 (96.0) 193 (96.0) 1.000 1371 (87.0) 457 (87.0) 1.000 
CHA2DS2-VASc score, median[IQR] 4 (3-5) 4 (3-5) 1.000 4 (3-4) 4 (3-4) 1.000 
Baseline pharmacotherapy 
     
Anticoagulation therapy, n (%) 603 (100.0) 201 (100.0) NA NA NA NA 
Vitamin K antagonists, n (%) 312 (51.7) 136 (67.7) <0.001 NA NA NA 
NOACs, n (%) 288 (47.8) 59 (29.4) <0.001 NA NA NA 
Heparin, n (%) 13 (2.2) 8 (4.0) 0.251 NA NA NA 
Calcium channel blockers, n (%) 183 (30.3) 68 (33.8) 0.404 407 (25.8) 127 (24.2) 0.487 
Beta blockers, n (%) 441 (73.1) 136 (67.7) 0.161 783 (49.7) 265 (50.5) 0.801 
Non loop diuretics, n (%) 231 (38.3) 91 (45.3) 0.096 563 (35.7) 206 (39.2) 0.166 
Renin angiotensin inhibitors, n (%) 295 (48.9) 87 (43.3) 0.192 540 (34.3) 164 (31.2) 0.220 
Adrenerg blockers, n (%) 4 ( 0.7) <3 0.563 18 (1.1) 6 (1.1) 1.000 
Statins, n (%) 214 (35.5) 56 (27.9) 0.058 362 (23.0) 85 (16.2) 0.001 












BC: Breast cancer. AF: atrial fibrillation. CHA2DS2-VASc score: (congestive heart failure, 
hypertension, age ≥75 years, diabetes, stroke/transient ischemic attack/thromboembolism, 
vascular disease, age 65-74 years, sex category). NOAC: Novel oral anticoagulation. 
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